Person · CIK 1578200

David P Schenkein

Director at Prime Medicine, Denali Therapeutics and Regeneron Pharmaceuticals

Earlier: Agios Pharmaceuticals, bluebird bio and Foundation Medicine

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$70.8M

Noticed on Form 144$6.5M

Bought on Form 4$350K

Companies6

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Prime Medicine PRME	Stock Option (right to buy) exercise $3.06, expires Jun 5, 2036, into Common Stock	Directly	75,000	Jun 5, 2026 · Filing · EDGAR
Denali Therapeutics DNLI	Common Stock	Directly	21,665	Jun 3, 2026 · Filing · EDGAR
Denali Therapeutics DNLI	Common Stock	See footnote	31,232	Jun 3, 2026 · Filing · EDGAR
Denali Therapeutics DNLI	Stock Option (right to buy) exercise $19.66, expires Jun 3, 2036, into Common Stock	Directly	19,226	Jun 3, 2026 · Filing · EDGAR
Regeneron Pharmaceuticals REGN	Common Stock	Directly	603	Jan 2, 2026 · Filing · EDGAR
Regeneron Pharmaceuticals REGN	Non-Qualified Stock Option (right to buy) exercise $772.76, expires Jan 2, 2036, into Common Stock	Directly	1,962	Jan 2, 2026 · Filing · EDGAR
Agios Pharmaceuticals	Common stock	Directly	126,242	Jun 13, 2024 · Filing · EDGAR
Agios Pharmaceuticals	Common stock	See footnote	79,082	Jun 13, 2024 · Filing · EDGAR
Agios Pharmaceuticals	Stock options (right to buy) exercise $42.45, expires Jun 20, 2034, into Common stock	Directly	11,774	Jun 20, 2024 · Filing · EDGAR
Agios Pharmaceuticals	Restricted stock units into Common stock	Directly	2,120	Jun 20, 2024 · Filing · EDGAR
bluebird bio	Common Stock	Directly	6,832	Jun 18, 2020 · Filing · EDGAR
bluebird bio	Stock Option (right to buy) exercise $64.09, expires Jun 18, 2030, into Common Stock	Directly	3,000	Jun 18, 2020 · Filing · EDGAR
Foundation Medicine	Common Stock	Directly	23,326	Jun 16, 2016 · Filing · EDGAR
Foundation Medicine	Common Stock	David P. Schenkein 2004 Revocable Trust	5,254	Jun 16, 2016 · Filing · EDGAR
Foundation Medicine	Common Stock	Amy P. Schenkein 2004 Revocable Trust	5,254	Jun 16, 2016 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)	Bought (Form 4)
Q4 2024	$1.9M	$1.9M	—
Q1 2024	$4.7M	$4.6M	—
Q2 2023	$374K	—	—
Q1 2023	$3.1M	Not machine-readable	—
Q4 2020	$5.9M	Not machine-readable	—
Q4 2019	—	—	$250K
Q2 2018	$11.9M	Not machine-readable	—
Q1 2018	$11.6M	Not machine-readable	—
Q4 2017	$6.8M	Not machine-readable	—
Q3 2017	$4.7M	Not machine-readable	—
Q2 2017	$476K	Not machine-readable	—
Q1 2017	$899K	Not machine-readable	—
Q4 2015	$321K	Not machine-readable	—
Q3 2015	$885K	Not machine-readable	—
Q2 2015	$4.7M	Not machine-readable	—
Q1 2015	$3.9M	Not machine-readable	—
Q4 2014	$3.1M	Not machine-readable	$100K
Q3 2014	$5.5M	Not machine-readable	—

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Denali Therapeutics DNLI · Morgan Stanley Smith Barney · 10b5-1 plan adopted Aug 12, 2024 · 1 notice
Nov 11, 2024	59,441 · ~$1.9M	Nov 11, 2024	Sold as noticed Sold 59,441 in 2 sales, Nov 11 to Nov 11 · $1.9M Form 4	Filing · EDGAR
Agios Pharmaceuticals · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 2 notices
Feb 27, 2024	57,471 · ~$2M	Feb 27, 2024	Sold as noticed Sold 57,471 at $34.89 on Feb 27 · $2M Form 4	Filing · EDGAR
Feb 26, 2024	80,000 · ~$2.6M	Feb 23, 2024	Sold as noticed Sold 80,000 in 3 sales, Feb 23 to Feb 27 · $2.7M Form 4 (1) · Form 4 (2)	Filing · EDGAR
Sales without a matching Form 144 · 104 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 16,363 at $22.85 on Apr 3, 2023 · $374K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 20,000 at $22.15 on Mar 27, 2023 · $443K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 1,667 at $22.72 on Mar 13, 2023 · $38K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 18,333 at $22.47 on Mar 13, 2023 · $412K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 20,000 at $25.37 on Feb 27, 2023 · $507K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 20,000 at $28.62 on Feb 13, 2023 · $572K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 3,300 at $29.88 on Jan 30, 2023 · $99K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 16,700 at $29.22 on Jan 30, 2023 · $488K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 1,034 at $29.49 on Jan 17, 2023 · $30K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 18,966 at $28.82 on Jan 17, 2023 · $547K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Denali Therapeutics (DNLI): Sold 5,000 at $90.01 on Dec 21, 2020 · $450K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Denali Therapeutics (DNLI): Sold 25,000 at $90.06 on Dec 21, 2020 · $2.3M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Denali Therapeutics (DNLI): Sold 30,000 at $70.05 on Nov 12, 2020 · $2.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Denali Therapeutics (DNLI): Sold 10,000 at $60.03 on Nov 10, 2020 · $600K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Denali Therapeutics (DNLI): Sold 10,000 at $50.18 on Nov 4, 2020 · $502K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 100 at $96.91 on Jun 1, 2018 · $10K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 3,190 at $96.40 on Jun 1, 2018 · $308K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 8,200 at $95.11 on Jun 1, 2018 · $780K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 1,510 at $94.37 on Jun 1, 2018 · $142K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 45,626 at $90.07 on May 30, 2018 · $4.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 299 at $92.03 on May 23, 2018 · $28K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 9,301 at $91.60 on May 23, 2018 · $852K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 39,774 at $90.11 on May 23, 2018 · $3.6M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 100 at $84.35 on May 1, 2018 · $8K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 2,814 at $83.56 on May 1, 2018 · $235K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 10,086 at $82.88 on May 1, 2018 · $836K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 2,113 at $79.49 on Apr 2, 2018 · $168K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 3,390 at $78.59 on Apr 2, 2018 · $266K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 3,340 at $77.76 on Apr 2, 2018 · $260K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 2,600 at $76.40 on Apr 2, 2018 · $199K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 1,557 at $75.54 on Apr 2, 2018 · $118K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 10,085 at $81.30 on Mar 1, 2018 · $820K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 2,915 at $80.38 on Mar 1, 2018 · $234K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 4,460 at $79.23 on Feb 1, 2018 · $353K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 8,540 at $78.50 on Feb 1, 2018 · $670K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 2,966 at $82.22 on Jan 26, 2018 · $244K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 11,369 at $81.40 on Jan 26, 2018 · $925K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 9,237 at $80.35 on Jan 26, 2018 · $742K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 20 at $80.01 on Jan 24, 2018 · $2K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 13,533 at $80.01 on Jan 24, 2018 · $1.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 32,875 at $80.01 on Jan 23, 2018 · $2.6M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,597 at $74.80 on Jan 16, 2018 · $493K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 10,914 at $74.11 on Jan 16, 2018 · $809K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 22,304 at $73.02 on Jan 16, 2018 · $1.6M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 13,185 at $71.77 on Jan 16, 2018 · $946K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 400 at $62.08 on Dec 1, 2017 · $25K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 5,600 at $61.51 on Dec 1, 2017 · $344K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 4,260 at $63.32 on Nov 1, 2017 · $270K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 942 at $64.64 on Nov 1, 2017 · $61K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 598 at $65.42 on Nov 1, 2017 · $39K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 200 at $66.75 on Nov 1, 2017 · $13K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 80,000 at $70.14 on Oct 4, 2017 · $5.6M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,000 at $66.76 on Oct 2, 2017 · $401K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 35,000 at $67.12 on Sep 18, 2017 · $2.3M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,000 at $62.20 on Sep 1, 2017 · $373K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable bluebird bio: Sold 2,000 at $115.07 on Aug 31, 2017 · $230K	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 24,000 at $60.55 on Aug 2, 2017 · $1.5M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 3,000 at $55.12 on Aug 1, 2017 · $165K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 3,000 at $51.18 on Jul 3, 2017 · $154K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 1,900 at $50.02 on Jun 7, 2017 · $95K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 1,100 at $50.02 on Jun 6, 2017 · $55K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 3,000 at $50.06 on May 1, 2017 · $150K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 3,000 at $58.62 on Apr 3, 2017 · $176K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 3,000 at $50.47 on Mar 1, 2017 · $151K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable bluebird bio: Sold 5,000 at $89.53 on Mar 1, 2017 · $448K	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,000 at $50.01 on Feb 16, 2017 · $300K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 4,000 at $80.26 on Oct 27, 2015 · $321K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 8,000 at $110.60 on Aug 3, 2015 · $885K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,500 at $120.67 on Jun 1, 2015 · $784K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,500 at $120.67 on Jun 1, 2015 · $784K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 8,929 at $120.05 on May 27, 2015 · $1.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 2,093 at $110.03 on May 12, 2015 · $230K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 3,107 at $110.01 on May 11, 2015 · $342K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 1,300 at $101.32 on May 8, 2015 · $132K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 2,600 at $101.32 on May 8, 2015 · $263K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 3,900 at $93.63 on May 1, 2015 · $365K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 1,300 at $100.03 on Apr 13, 2015 · $130K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 2,600 at $100.03 on Apr 13, 2015 · $260K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 3,900 at $92.54 on Apr 1, 2015 · $361K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 2,600 at $110.16 on Mar 5, 2015 · $286K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 1,300 at $107.05 on Mar 2, 2015 · $139K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,500 at $107.05 on Mar 2, 2015 · $696K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 684 at $120.31 on Feb 13, 2015 · $82K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 787 at $120.14 on Feb 11, 2015 · $95K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 3,900 at $114.31 on Feb 2, 2015 · $446K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,500 at $114.31 on Feb 2, 2015 · $743K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,500 at $110.08 on Jan 2, 2015 · $716K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,500 at $110.08 on Jan 2, 2015 · $716K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,500 at $97.03 on Dec 1, 2014 · $631K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,500 at $97.03 on Dec 1, 2014 · $631K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,500 at $81.71 on Nov 3, 2014 · $531K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,500 at $81.71 on Nov 3, 2014 · $531K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,500 at $60.07 on Oct 1, 2014 · $390K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,500 at $60.07 on Oct 1, 2014 · $390K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 30,000 at $62.68 on Sep 26, 2014 · $1.9M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 30,000 at $62.68 on Sep 26, 2014 · $1.9M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,500 at $46.30 on Sep 2, 2014 · $301K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,500 at $46.30 on Sep 2, 2014 · $301K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 2,265 at $40.17 on Aug 11, 2014 · $91K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 2,265 at $40.17 on Aug 11, 2014 · $91K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 4,235 at $39.17 on Aug 1, 2014 · $166K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 4,235 at $39.17 on Aug 1, 2014 · $166K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,500 at $46.52 on Jul 1, 2014 · $302K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Agios Pharmaceuticals: Sold 6,500 at $46.52 on Jul 1, 2014 · $302K (10b5-1 plan)	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Prime Medicine PRME Director · filings 2022 to 2026

Date	Transaction	Shares	Held after	Source
Jun 5, 2026	Grant or award from the company Stock Option (right to buy)	+75,000	75,000 direct	Filing · EDGAR
Aug 1, 2025	Returned to the company Stock Option (right to buy)	−39,062	0 direct	Filing · EDGAR
Aug 1, 2025	Grant or award from the company Stock Option (right to buy)	+39,062	39,062 direct	Filing · EDGAR
Aug 1, 2025	Returned to the company Stock Option (right to buy)	−45,000	0 direct	Filing · EDGAR
Aug 1, 2025	Grant or award from the company Stock Option (right to buy)	+45,000	45,000 direct	Filing · EDGAR
Jun 4, 2025	Grant or award from the company Stock Option (right to buy)	+55,000	55,000 direct	Filing · EDGAR
Jun 12, 2024	Grant or award from the company Stock Option (right to buy)	+45,000	45,000 direct	Filing · EDGAR
Jun 14, 2023	Grant or award from the company Stock Option (right to buy)	+39,062	39,062 direct	Filing · EDGAR

Denali Therapeutics DNLI Director · filings 2017 to 2026 · sold $7.8M · $1.9M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 3, 2026	Grant or award from the company	+6,408			21,665 direct	Filing · EDGAR
Jun 3, 2026	Grant or award from the company Stock Option (right to buy)	+19,226			19,226 direct	Filing · EDGAR
Jun 3, 2025	Grant or award from the company	+6,037			15,257 direct	Filing · EDGAR
Jun 3, 2025	Grant or award from the company Stock Option (right to buy)	+18,111			18,111 direct	Filing · EDGAR
Nov 11, 2024	Option or RSU exercised or converted	+47,165	$18.00	$849K	68,661 direct	Filing · EDGAR
Nov 11, 2024	Sale under a 10b5-1 plan	−27,129	$32.09	$871K	41,532 direct	Filing · EDGAR
Nov 11, 2024	Sale under a 10b5-1 plan	−32,312	$32.87	$1.1M	9,220 direct	Filing · EDGAR
Nov 11, 2024	Option or RSU exercised or converted Stock Option (right to buy)	−47,165			0 direct	Filing · EDGAR
May 31, 2024	Grant or award from the company	+5,967			21,496 direct	Filing · EDGAR
May 31, 2024	Grant or award from the company Stock Option (right to buy)	+17,901			17,901 direct	Filing · EDGAR
Jun 1, 2023	Grant or award from the company	+4,216			15,529 direct	Filing · EDGAR
Jun 1, 2023	Grant or award from the company Stock Option (right to buy)	+12,649			12,649 direct	Filing · EDGAR
Jun 2, 2022	Grant or award from the company	+5,986			11,313 direct	Filing · EDGAR
Jun 2, 2022	Grant or award from the company Stock Option (right to buy)	+17,959			17,959 direct	Filing · EDGAR
Jun 2, 2021	Grant or award from the company	+2,074			5,327 direct	Filing · EDGAR
Jun 2, 2021	Grant or award from the company Stock Option (right to buy)	+6,222			6,222 direct	Filing · EDGAR
Jun 1, 2021	Option or RSU exercised or converted	+3,253			3,253 direct	Filing · EDGAR
Jun 1, 2021	Option or RSU exercised or converted Restricted Stock Units	−3,253			0 direct	Filing · EDGAR
Dec 21, 2020	Sale under a 10b5-1 plan	−25,000	$90.06	$2.3M	0 direct	Filing · EDGAR
Dec 21, 2020	Sale under a 10b5-1 plan	−5,000	$90.01	$450K	26,232 See footnote	Filing · EDGAR
Nov 12, 2020	Sale under a 10b5-1 plan	−30,000	$70.05	$2.1M	25,000 direct	Filing · EDGAR
Nov 10, 2020	Sale under a 10b5-1 plan	−10,000	$60.03	$600K	55,000 direct	Filing · EDGAR
Nov 4, 2020	Sale under a 10b5-1 plan	−10,000	$50.18	$502K	65,000 direct	Filing · EDGAR
Jun 3, 2020	Grant or award from the company Stock Option (right to buy)	+15,183			15,183 direct	Filing · EDGAR
Jun 3, 2020	Grant or award from the company Restricted Stock Units	+3,253			3,253 direct	Filing · EDGAR
May 30, 2019	Grant or award from the company Stock Option (right to buy)	+27,245			27,245 direct	Filing · EDGAR
Jun 13, 2018	Grant or award from the company Stock Option (right to buy)	+27,830			27,830 direct	Filing · EDGAR
Dec 12, 2017	Derivative converted	+105,225			105,225 See footnote	Filing · EDGAR
Dec 12, 2017	Derivative converted	+19,774			19,774 See footnote	Filing · EDGAR
Dec 12, 2017	Derivative converted	+105,225			105,225 See footnote	Filing · EDGAR
Dec 12, 2017	Derivative converted	+19,774			19,774 See footnote	Filing · EDGAR
Dec 12, 2017	Derivative converted Series A-1 Preferred Stock	−105,225			0 See footnote	Filing · EDGAR
Dec 12, 2017	Derivative converted Series A-1 Preferred Stock	−19,774			0 See footnote	Filing · EDGAR
Dec 12, 2017	Derivative converted Series A-1 Preferred Stock	−105,225			0 See footnote	Filing · EDGAR
Dec 12, 2017	Derivative converted Series A-1 Preferred Stock	−19,774			0 See footnote	Filing · EDGAR
Dec 7, 2017	Grant or award from the company Stock Option (right to buy)	+47,165			47,165 direct	Filing · EDGAR

Regeneron Pharmaceuticals REGN Director · filings 2023 to 2026

Date	Transaction	Shares	Held after	Source
Jan 2, 2026	Grant or award from the company	+155	603 direct	Filing · EDGAR
Jan 2, 2026	Grant or award from the company Non-Qualified Stock Option (right to buy)	+1,962	1,962 direct	Filing · EDGAR
Jan 2, 2025	Grant or award from the company	+166	448 direct	Filing · EDGAR
Jan 2, 2025	Grant or award from the company Non-Qualified Stock Option (right to buy)	+1,958	1,958 direct	Filing · EDGAR
Jan 2, 2024	Grant or award from the company	+42	282 direct	Filing · EDGAR
Jan 2, 2024	Grant or award from the company Non-Qualified Stock Option (right to buy)	+508	508 direct	Filing · EDGAR
Sep 8, 2023	Grant or award from the company	+240	240 direct	Filing · EDGAR
Sep 8, 2023	Grant or award from the company Non-Qualified Stock Option (right to buy)	+2,739	2,739 direct	Filing · EDGAR

Agios Pharmaceuticals Chief Executive Officer · filings 2013 to 2024 · sold $62.3M · bought $250K · $4.6M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 20, 2024	Grant or award from the company Restricted stock units	+2,120			2,120 direct	Filing · EDGAR
Jun 20, 2024	Grant or award from the company Stock options (right to buy)	+11,774			11,774 direct	Filing · EDGAR
Jun 13, 2024	Option or RSU exercised or converted	+3,388			126,242 direct	Filing · EDGAR
Jun 13, 2024	Option or RSU exercised or converted Restricted stock units	−3,388			0 direct	Filing · EDGAR
Feb 27, 2024	Option or RSU exercised or converted	+11,858	$31.64	$375K	134,712 direct	Filing · EDGAR
Feb 27, 2024	Open-market or private sale	−11,858	$33.60	$398K	122,854 direct	Filing · EDGAR
Feb 27, 2024	Option or RSU exercised or converted	+57,471	$31.64	$1.8M	180,325 direct	Filing · EDGAR
Feb 27, 2024	Open-market or private sale	−57,471	$34.89	$2M	122,854 direct	Filing · EDGAR
Feb 27, 2024	Option or RSU exercised or converted Stock option (right to buy)	−11,858			57,471 direct	Filing · EDGAR
Feb 27, 2024	Option or RSU exercised or converted Stock option (right to buy)	−57,471			0 direct	Filing · EDGAR
Feb 26, 2024	Option or RSU exercised or converted	+20,411	$31.64	$646K	143,265 direct	Filing · EDGAR
Feb 26, 2024	Open-market or private sale	−20,411	$33.19	$677K	122,854 direct	Filing · EDGAR
Feb 26, 2024	Option or RSU exercised or converted Stock option (right to buy)	−20,411			69,329 direct	Filing · EDGAR
Feb 23, 2024	Option or RSU exercised or converted	+47,731	$31.64	$1.5M	170,585 direct	Filing · EDGAR
Feb 23, 2024	Open-market or private sale	−47,731	$33.05	$1.6M	122,854 direct	Filing · EDGAR
Feb 23, 2024	Option or RSU exercised or converted Stock option (right to buy)	−47,731			89,740 direct	Filing · EDGAR
Jun 21, 2023	Option or RSU exercised or converted	+4,975			122,854 direct	Filing · EDGAR
Jun 21, 2023	Option or RSU exercised or converted Restricted stock unit	−4,975			0 direct	Filing · EDGAR
Jun 13, 2023	Grant or award from the company Restricted stock units	+3,388			3,388 direct	Filing · EDGAR
Jun 13, 2023	Grant or award from the company Stock options (right to buy)	+18,958			18,958 direct	Filing · EDGAR
Apr 3, 2023	Option or RSU exercised or converted	+16,363	$9.05	$148K	134,242 direct	Filing · EDGAR
Apr 3, 2023	Sale under a 10b5-1 plan	−16,363	$22.85	$374K	117,879 direct	Filing · EDGAR
Apr 3, 2023	Option or RSU exercised or converted Stock option (right to buy)	−16,363			0 direct	Filing · EDGAR
Mar 27, 2023	Option or RSU exercised or converted	+20,000	$9.05	$181K	137,879 direct	Filing · EDGAR
Mar 27, 2023	Sale under a 10b5-1 plan	−20,000	$22.15	$443K	117,879 direct	Filing · EDGAR
Mar 27, 2023	Option or RSU exercised or converted Stock option (right to buy)	−20,000			16,363 direct	Filing · EDGAR
Mar 13, 2023	Option or RSU exercised or converted	+20,000	$9.05	$181K	137,879 direct	Filing · EDGAR
Mar 13, 2023	Sale under a 10b5-1 plan	−18,333	$22.47	$412K	119,546 direct	Filing · EDGAR
Mar 13, 2023	Sale under a 10b5-1 plan	−1,667	$22.72	$38K	117,879 direct	Filing · EDGAR
Mar 13, 2023	Option or RSU exercised or converted Stock option (right to buy)	−20,000			36,363 direct	Filing · EDGAR
Feb 27, 2023	Option or RSU exercised or converted	+20,000	$9.05	$181K	137,879 direct	Filing · EDGAR
Feb 27, 2023	Sale under a 10b5-1 plan	−20,000	$25.37	$507K	117,879 direct	Filing · EDGAR
Feb 27, 2023	Option or RSU exercised or converted Stock option (right to buy)	−20,000			56,363 direct	Filing · EDGAR
Feb 13, 2023	Option or RSU exercised or converted	+20,000	$9.05	$181K	137,879 direct	Filing · EDGAR
Feb 13, 2023	Sale under a 10b5-1 plan	−20,000	$28.62	$572K	117,879 direct	Filing · EDGAR
Feb 13, 2023	Option or RSU exercised or converted Stock option (right to buy)	−20,000			76,363 direct	Filing · EDGAR
Jan 30, 2023	Option or RSU exercised or converted	+20,000	$9.05	$181K	137,879 direct	Filing · EDGAR
Jan 30, 2023	Sale under a 10b5-1 plan	−16,700	$29.22	$488K	121,179 direct	Filing · EDGAR
Jan 30, 2023	Sale under a 10b5-1 plan	−3,300	$29.88	$99K	117,879 direct	Filing · EDGAR
Jan 30, 2023	Option or RSU exercised or converted Stock option (right to buy)	−20,000			96,363 direct	Filing · EDGAR
Jan 17, 2023	Option or RSU exercised or converted	+20,000	$9.05	$181K	137,879 direct	Filing · EDGAR
Jan 17, 2023	Sale under a 10b5-1 plan	−18,966	$28.82	$547K	118,913 direct	Filing · EDGAR
Jan 17, 2023	Sale under a 10b5-1 plan	−1,034	$29.49	$30K	117,879 direct	Filing · EDGAR
Jan 17, 2023	Option or RSU exercised or converted Stock option (right to buy)	−20,000			116,363 direct	Filing · EDGAR
Jun 21, 2022	Grant or award from the company Restricted stock unit	+4,975			4,975 direct	Filing · EDGAR
Jun 21, 2022	Grant or award from the company Stock options (right to buy)	+29,307			29,307 direct	Filing · EDGAR
May 20, 2022	Option or RSU exercised or converted	+1,585			117,879 direct	Filing · EDGAR
May 20, 2022	Option or RSU exercised or converted Restricted stock unit	−1,585			0 direct	Filing · EDGAR
Feb 22, 2022	Option or RSU exercised or converted	+2,775			117,052 direct	Filing · EDGAR
Feb 22, 2022	Shares withheld for tax or exercise price	−758	$29.08	$22K	116,294 direct	Filing · EDGAR
Feb 22, 2022	Option or RSU exercised or converted Restricted stock units	−2,775			0 direct	Filing · EDGAR
May 28, 2021	Option or RSU exercised or converted	+1,686			114,277 direct	Filing · EDGAR
May 28, 2021	Option or RSU exercised or converted Restricted stock units	−1,686			0 direct	Filing · EDGAR
May 20, 2021	Grant or award from the company Restricted stock unit	+1,585			1,585 direct	Filing · EDGAR
May 20, 2021	Grant or award from the company Stock options (right to buy)	+8,888			8,888 direct	Filing · EDGAR
Feb 22, 2021	Option or RSU exercised or converted	+2,774			113,412 direct	Filing · EDGAR
Feb 22, 2021	Shares withheld for tax or exercise price	−821			112,591 direct	Filing · EDGAR
Feb 22, 2021	Option or RSU exercised or converted Restricted stock units	−2,774			2,775 direct	Filing · EDGAR
Feb 16, 2021	Option or RSU exercised or converted	+8,125			113,178 direct	Filing · EDGAR
Feb 16, 2021	Shares withheld for tax or exercise price	−2,540			110,638 direct	Filing · EDGAR

206 earlier transactions are in the filing list below.

bluebird bio Director · filings 2013 to 2020 · sold $678K · bought $100K

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 18, 2020	Grant or award from the company	+156			5,332 direct	Filing · EDGAR
Jun 18, 2020	Grant or award from the company	+1,500			6,832 direct	Filing · EDGAR
Jun 18, 2020	Grant or award from the company Stock Option (right to buy)	+3,000			3,000 direct	Filing · EDGAR
Jun 6, 2019	Grant or award from the company	+1,000			5,176 direct	Filing · EDGAR
Jun 6, 2019	Grant or award from the company Stock Option (right to buy)	+4,000			4,000 direct	Filing · EDGAR
Jun 20, 2018	Grant or award from the company	+1,000			4,176 direct	Filing · EDGAR
Jun 20, 2018	Grant or award from the company Stock Option (right to buy)	+4,000			4,000 direct	Filing · EDGAR
Aug 31, 2017	Option or RSU exercised or converted	+2,000	$8.16	$16K	5,176 direct	Filing · EDGAR
Aug 31, 2017	Open-market or private sale	−2,000	$115.07	$230K	3,176 direct	Filing · EDGAR
Aug 31, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−2,000			19,361 direct	Filing · EDGAR
Jun 8, 2017	Grant or award from the company	+1,000			3,176 direct	Filing · EDGAR
Jun 8, 2017	Grant or award from the company Stock Option (right to buy)	+4,000			4,000 direct	Filing · EDGAR
Mar 1, 2017	Option or RSU exercised or converted	+5,000	$8.16	$41K	7,176 direct	Filing · EDGAR
Mar 1, 2017	Open-market or private sale	−5,000	$89.53	$448K	2,176 direct	Filing · EDGAR
Mar 1, 2017	Option or RSU exercised or converted Stock Option (right to buy)	−5,000			21,361 direct	Filing · EDGAR
Jun 2, 2016	Grant or award from the company	+1,000			2,176 direct	Filing · EDGAR
Jun 2, 2016	Grant or award from the company Stock Option (right to buy)	+4,000			4,000 direct	Filing · EDGAR
Jun 4, 2015	Grant or award from the company Stock Option (right to buy)	+7,500			7,500 direct	Filing · EDGAR
Dec 19, 2014	Open-market or private purchase	+1,176	$85.00	$100K	1,176 direct	Filing · EDGAR
Jun 11, 2014	Grant or award from the company Stock Option (right to buy)	+7,500			7,500 direct	Filing · EDGAR

Foundation Medicine Director · filings 2013 to 2016

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 16, 2016	Grant or award from the company	+12,075	$19.93	$241K	23,326 direct	Filing · EDGAR
Jun 18, 2015	Grant or award from the company	+5,997	$32.23	$193K	11,251 direct	Filing · EDGAR
Apr 7, 2015	Tendered in a change of control	−25,996	$50.00	$1.3M	5,254 direct	Filing · EDGAR
Apr 7, 2015	Tendered in a change of control	−25,996	$50.00	$1.3M	5,254 David P. Schenkein 2004 Revocable Trust	Filing · EDGAR
Apr 7, 2015	Tendered in a change of control	−25,996	$50.00	$1.3M	5,254 Amy P. Schenkein 2004 Revocable Trust	Filing · EDGAR
Jun 18, 2014	Grant or award from the company Stock Option (right to buy)	+13,385			13,385 direct	Filing · EDGAR
Sep 30, 2013	Derivative converted	+31,250			31,250 David P. Schenkein 2004 Revocable Trust	Filing · EDGAR
Sep 30, 2013	Derivative converted	+31,250			31,250 Amy P. Schenkein 2004 Revocable Trust	Filing · EDGAR
Sep 30, 2013	Derivative converted Series A Convertible Preferred Stock	−125,000			0 David P. Schenkein 2004 Revocable Trust	Filing · EDGAR
Sep 30, 2013	Derivative converted Series A Convertible Preferred Stock	−125,000			0 Amy P. Schenkein 2004 Revocable Trust	Filing · EDGAR

All 139 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Jun 8, 2026	Form 4	Prime Medicine PRME	Filing · EDGAR
Jun 5, 2026	Form 4	Denali Therapeutics DNLI	Filing · EDGAR
Jan 6, 2026	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Aug 5, 2025	Form 4	Prime Medicine PRME	Filing · EDGAR
Jun 5, 2025	Form 4	Denali Therapeutics DNLI	Filing · EDGAR
Jun 5, 2025	Form 4	Prime Medicine PRME	Filing · EDGAR
Jan 6, 2025	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Nov 13, 2024	Form 4	Denali Therapeutics DNLI	Filing · EDGAR
Nov 12, 2024	Form 144	Denali Therapeutics DNLI	Filing · EDGAR
Jun 24, 2024	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jun 17, 2024	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jun 14, 2024	Form 4	Prime Medicine PRME	Filing · EDGAR
Jun 4, 2024	Form 4	Denali Therapeutics DNLI	Filing · EDGAR
Feb 29, 2024	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Feb 27, 2024	Form 144	Agios Pharmaceuticals	Filing · EDGAR
Feb 27, 2024	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Feb 26, 2024	Form 144	Agios Pharmaceuticals	Filing · EDGAR
Jan 4, 2024	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Sep 12, 2023	Form 4	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Sep 12, 2023	Form 3	Regeneron Pharmaceuticals REGN	Filing · EDGAR
Jun 23, 2023	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jun 16, 2023	Form 4	Prime Medicine PRME	Filing · EDGAR
Jun 15, 2023	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jun 5, 2023	Form 4	Denali Therapeutics DNLI	Filing · EDGAR
Apr 5, 2023	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Mar 29, 2023	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Mar 15, 2023	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Mar 1, 2023	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Feb 15, 2023	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Feb 1, 2023	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jan 19, 2023	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Oct 19, 2022	Form 3	Prime Medicine PRME	Filing · EDGAR
Jun 23, 2022	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jun 6, 2022	Form 4	Denali Therapeutics DNLI	Filing · EDGAR
May 24, 2022	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Feb 23, 2022	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jun 4, 2021	Form 4	Denali Therapeutics DNLI	Filing · EDGAR
Jun 3, 2021	Form 4	Denali Therapeutics DNLI	Filing · EDGAR
Jun 2, 2021	Form 4	Agios Pharmaceuticals	Filing · EDGAR
May 24, 2021	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Feb 24, 2021	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Feb 17, 2021	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Dec 23, 2020	Form 4	Denali Therapeutics DNLI	Filing · EDGAR
Nov 13, 2020	Form 4	Denali Therapeutics DNLI	Filing · EDGAR
Nov 12, 2020	Form 4	Denali Therapeutics DNLI	Filing · EDGAR
Nov 6, 2020	Form 4	Denali Therapeutics DNLI	Filing · EDGAR
Jun 22, 2020	Form 4	bluebird bio	Filing · EDGAR
Jun 5, 2020	Form 4	Denali Therapeutics DNLI	Filing · EDGAR
Jun 1, 2020	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Feb 25, 2020	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Feb 19, 2020	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Nov 15, 2019	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jun 10, 2019	Form 4	bluebird bio	Filing · EDGAR
Jun 3, 2019	Form 4	Denali Therapeutics DNLI	Filing · EDGAR
Feb 26, 2019	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Feb 20, 2019	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Nov 19, 2018	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Sep 12, 2018	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Sep 7, 2018	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jun 22, 2018	Form 4	bluebird bio	Filing · EDGAR
Jun 15, 2018	Form 4	Denali Therapeutics DNLI	Filing · EDGAR
Jun 5, 2018	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jun 1, 2018	Form 4	Agios Pharmaceuticals	Filing · EDGAR
May 29, 2018	Form 4	Agios Pharmaceuticals	Filing · EDGAR
May 3, 2018	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Apr 4, 2018	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Mar 5, 2018	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Feb 20, 2018	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Feb 5, 2018	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jan 30, 2018	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jan 26, 2018	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jan 25, 2018	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jan 25, 2018	Form 4/A	Agios Pharmaceuticals	Filing · EDGAR
Jan 16, 2018	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Dec 12, 2017	Form 4	Denali Therapeutics DNLI	Filing · EDGAR
Dec 8, 2017	Form 4	Denali Therapeutics DNLI	Filing · EDGAR
Dec 7, 2017	Form 3	Denali Therapeutics DNLI	Filing · EDGAR
Dec 5, 2017	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Nov 3, 2017	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Oct 5, 2017	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Oct 4, 2017	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Sep 20, 2017	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Sep 5, 2017	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Sep 5, 2017	Form 4	bluebird bio	Filing · EDGAR
Aug 3, 2017	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jul 6, 2017	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jun 12, 2017	Form 4	bluebird bio	Filing · EDGAR
Jun 8, 2017	Form 4	Agios Pharmaceuticals	Filing · EDGAR
May 2, 2017	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Apr 5, 2017	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Mar 3, 2017	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Mar 3, 2017	Form 4	bluebird bio	Filing · EDGAR
Feb 23, 2017	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Feb 17, 2017	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jan 27, 2017	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jan 23, 2017	Form 4/A	bluebird bio	Filing · EDGAR
Jun 20, 2016	Form 4	Foundation Medicine	Filing · EDGAR
Jun 3, 2016	Form 4	bluebird bio	Filing · EDGAR
Feb 18, 2016	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jan 11, 2016	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jan 5, 2016	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Dec 7, 2015	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Oct 30, 2015	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Aug 5, 2015	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jun 22, 2015	Form 4	Foundation Medicine	Filing · EDGAR
Jun 8, 2015	Form 4	bluebird bio	Filing · EDGAR
Jun 2, 2015	Form 4	Agios Pharmaceuticals	Filing · EDGAR
May 28, 2015	Form 4	Agios Pharmaceuticals	Filing · EDGAR
May 13, 2015	Form 4	Agios Pharmaceuticals	Filing · EDGAR
May 11, 2015	Form 4	Agios Pharmaceuticals	Filing · EDGAR
May 5, 2015	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Apr 15, 2015	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Apr 14, 2015	Form 4/A	Foundation Medicine	Filing · EDGAR
Apr 9, 2015	Form 4	Foundation Medicine	Filing · EDGAR
Apr 3, 2015	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Mar 9, 2015	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Mar 3, 2015	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Feb 13, 2015	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Feb 3, 2015	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jan 6, 2015	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Dec 22, 2014	Form 4	bluebird bio	Filing · EDGAR
Dec 2, 2014	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Nov 4, 2014	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Oct 3, 2014	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Sep 29, 2014	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Sep 3, 2014	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Aug 12, 2014	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Aug 5, 2014	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jul 2, 2014	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Jun 20, 2014	Form 4	Foundation Medicine	Filing · EDGAR
Jun 12, 2014	Form 4	bluebird bio	Filing · EDGAR
Apr 8, 2014	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Mar 27, 2014	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Mar 12, 2014	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Mar 7, 2014	Form 4	Agios Pharmaceuticals	Filing · EDGAR
Oct 2, 2013	Form 4	Foundation Medicine	Filing · EDGAR
Sep 24, 2013	Form 3	Foundation Medicine	Filing · EDGAR
Jul 23, 2013	Form 3	Agios Pharmaceuticals	Filing · EDGAR
Jun 18, 2013	Form 3	bluebird bio	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 10:14 PM ET. The filing on SEC.gov is the record.